Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Dec;1796(2):162-75.
doi: 10.1016/j.bbcan.2009.06.003. Epub 2009 Jun 13.

ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches

Jin-Qiang Chen  1 , Jose Russo
Affiliations
Review

ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches

Jin-Qiang Chen et al. Biochim Biophys Acta. 2009 Dec.

Abstract

Triple negative breast cancer (TNBC) is a type of aggressive breast cancer lacking the expression of estrogen receptors (ER), progesterone receptors (PR) and human epidermal growth factor receptor-2 (HER-2). TNBC patients account for approximately 15% of total breast cancer patients and are more prevalent among young African, African-American and Latino women patients. The currently available ER-targeted and Her-2-based therapies are not effective for treating TNBC. Recent studies have revealed a number of novel features of TNBC. In the present work, we comprehensively addressed these features and discussed potential therapeutic approaches based on these features for TNBC, with particular focus on: 1) the pathological features of TNBC/basal-like breast cancer; 2) E(2)/ERbeta-mediated signaling pathways; 3) G-protein coupling receptor-30/epithelial growth factor receptor (GPCR-30/EGFR) signaling pathway; 4) interactions of ERbeta with breast cancer 1/2 (BRCA1/2); 5) chemokine CXCL8 and related chemokines; 6) altered microRNA signatures and suppression of ERalpha expression/ERalpha-signaling by micro-RNAs; 7) altered expression of several pro-oncongenic and tumor suppressor proteins; and 8) genotoxic effects caused by oxidative estrogen metabolites. Gaining better insights into these molecular pathways in TNBC may lead to identification of novel biomarkers and targets for development of diagnostic and therapeutic approaches for prevention and treatment of TNBC.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Molecular Features of TNBC: 1)
E2/ERβ-mediated signaling pathways and Interaction with BRCA1; 2) E2/GRCP-30/EGFR signaling pathway; 3) CXCL8 and related CXC Chemokines; 4) MicroRNA signatures; 5) Notch/Suvivin; 6) Akt; 7) E-cadherin/E-Selectin and 8) Osteoponin are shown. Basic shapes filled with colors indicate increased expression; Basic shapes filled without color [148] indicate loss or reduced levels of the indicated proteins/receptors
See this image and copyright information in PMC

References

    1. Hergueta-Redondo M, Palacios J, Cano A, Moreno-Bueno G. "New" molecular taxonomy in breast cancer. Clin Transl Oncol. 2008;10:777–785. - PubMed
    1. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429–4434. - PubMed
    1. Kurebayashi J. Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics. Breast Cancer. 2009 - PubMed
    1. Hall JM, Couse JF, Korach KS. The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem. 2001;276:36869–36872. - PubMed
    1. Bolton JL, Thatcher GR. Potential mechanisms of estrogen quinone carcinogenesis. Chem Res Toxicol. 2008;21:93–101. - PMC - PubMed

Publication types

MeSH terms